Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds

被引：11

作者：

Riether, Doris ^{[2
]}

Zindell, Renee ^{[1
]}

Wu, Lifen ^{[1
]}

Betageri, Raj ^{[1
]}

Jenkins, James E. ^{[3
]}

Khor, Someina ^{[3
]}

Berry, Angela K. ^{[1
]}

Hickey, Eugene R. ^{[1
]}

Ermann, Monika ^{[3
]}

Albrecht, Claudia ^{[4
]}

Ceci, Angelo ^{[2
]}

Gemkow, Mark J. ^{[4
]}

Nagaraja, Nelamangala V. ^{[1
]}

Romig, Helmut ^{[2
]}

Sauer, Achim ^{[2
]}

Thomson, David S. ^{[1
]}

机构：

[1] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

[2] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach An Der Riss, Germany

[3] Evotec UK Ltd, Abingdon OX14 4RZ, Oxon, England

[4] Evotec AG, D-22419 Hamburg, Germany

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 03期

关键词：

Cannabinoid receptor 2 (CB2); Proline; Metabolic stability; Solubility; Pharmacokinetic properties; CANNABINOID RECEPTOR; NEUROPATHIC PAIN; EXPRESSION; EFFICACY; AFFINITY; LIGANDS; SYSTEM;

D O I：

10.1016/j.bmcl.2014.12.019

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Through a ligand-based pharmacophore model (S)-proline based compounds were identified as potent cannabinoid receptor 2 (CB2) agonists with high selectivity over the cannabinoid receptor 1 (CB1). Structure-activity relationship investigations for this compound class lead to oxo-proline compounds 21 and 22 which combine an impressive CB1 selectivity profile with good pharmacokinetic properties. In a streptozotocin induced diabetic neuropathy model, 22 demonstrated a dose-dependent reversal of mechanical hyperalgesia. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：581 / 586

页数：6

共 22 条

[1] Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons
Anand, Uma
Otto, William R.
Sanchez-Herrera, Daniel
Facer, Paul
Yiangou, Yiangos
Korchev, Yuri
Birch, Rolfe
Benham, Christopher
Bountra, Chas
Chessell, Iain P.
Anand, Praveen
[J]. PAIN, 2008, 138 (03) : 667 - 680
[2] CB2: a cannabinoid receptor with an identity crisis
Atwood, Brady K.
Mackie, Ken
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (03) : 467 - 479
[3] Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model
Bartolozzi, Alessandra
Cirillo, Pier Francesco
Berry, Angela K.
Hickey, Eugene R.
Thomson, David S.
Wu, Lifen
Zindell, Renee
Albrecht, Claudia
Ceci, Angelo
Gemkow, Mark J.
Nagaraja, Nelamangala V.
Romig, Helmut
Sauer, Achim
Riether, Doris
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 587 - 592
[4] Berry A., 2010, PCT Int. Appl, Patent No. [W02010077836, 2010077836]
[5] EXPRESSION OF CENTRAL AND PERIPHERAL CANNABINOID RECEPTORS IN HUMAN IMMUNE TISSUES AND LEUKOCYTE SUBPOPULATIONS
GALIEGUE, S
MARY, S
MARCHAND, J
DUSSOSSOY, D
CARRIERE, D
CARAYON, P
BOUABOULA, M
SHIRE, D
LEFUR, G
CASELLAS, P
[J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 232 (01): : 54 - 61
[6] Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB2 receptor
Gouldson, P
Calandra, B
Legoux, P
Kernéis, A
Rinaldi-Carmona, M
Barth, F
Le Fur, G
Ferrara, P
Shire, D
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 401 (01) : 17 - 25
[7] Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues
Griffin, G
Williams, S
Aung, MM
Razdan, RK
Martin, BR
Abood, ME
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (02) : 525 - 535
[8] Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists
Han, Sangdon
Thatte, Jayant
Buzard, Daniel J.
Jones, Robert M.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (21) : 8224 - 8256
[9] Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches
Hickey, Eugene R.
Zindell, Renee
Cirillo, Pier F.
Wu, Lifen
Ermann, Monika
Berry, Angela K.
Thomson, David S.
Albrecht, Claudia
Gemkow, Mark J.
Riether, Doris
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 575 - 580
[10] Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain
Hollinshead, Sean P.
Tidwell, Michael W.
Palmer, John
Guidetti, Rossella
Sanderson, Adam
Johnson, Michael P.
Chambers, Mark G.
Oskins, Jennifer
Stratford, Robert
Astles, Peter C.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) : 5722 - 5733

← 1 2 3 →